The therapeutic upregulation of MHC‐I has recently been shown to enhance the sensitivity of ICIs.[34] However, as MHC‐I is also expressed in nontumor cells, an increase in MHC‐I expression in vivo may cause autoimmune disorders.[35] Therefore, inhibition of G3BP1, a target present at high levels in BLCA cells, may be suitable for enhancing MHC‐I expression in BLCA cells. The gene discussed is G3BP1; the disease is bladder transitional cell carcinoma.